



Market Announcement

18 August 2023

Cleo Diagnostics Ltd (ASX: COV) – Admission and Quotation

Description

Cleo Diagnostics Ltd ('COV') was admitted to the Official List of ASX on Friday, 18 August 2023.

The securities of COV will commence quotation at 11:00 AM AEST on Tuesday, 22 August 2023.

COV raised \$12,000,000 pursuant to the offer under its replacement prospectus dated 6 July 2023 by the issue of 60,000,000 shares at an issue price of \$0.20 per share.

Quotation information

Quoted securities	Fully paid ordinary shares: 72,775,001
ASX code	Fully paid ordinary shares: COV
Time	11:00 AM AEST
Date	Tuesday, 22 August 2023
ASX trade abbreviation	CLEO DIAGN
ISIN	Fully paid ordinary shares: AU0000288045
Registered office	Address: Level 2, 480 Collins Street, Melbourne VIC 3000 Phone: 03 9614 0600 Email: pauline.moffatt@cleodx.com
Company secretary	Pauline Moffatt
Share Registry	XCEND Pty Ltd Address: C/- Level 2, 145 William Street, Darlinghurst NSW 2010 Phone: 02 7208 8033 Email: ann.nguyen@xcend.co
Balance date	30 June
CHESS	Participating. CHESS and Issuer Sponsored.
Place of incorporation	Victoria
Dividend policy	See section 2.9 of the Replacement Prospectus
Activities	Medical diagnostics/devices development and commercialisation
Lead manager	Taylor Collison Limited
Underwriter	NA
ASX restricted securities	46,900,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 22 August 2025, being 24 months from the date of Quotation.

For personal use only

37,500 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 19 September 2023, being 12 months from the date of issue.

125,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 21 September 2023, being 12 months from the date of issue.

150,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 30 September 2023, being 12 months from the date of issue.

100,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 13 October 2023, being 12 months from the date of issue.

150,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 18 October 2023, being 12 months from the date of issue.

75,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 19 October 2023, being 12 months from the date of issue.

425,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 21 October 2023, being 12 months from the date of issue.

50,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 4 November 2023, being 12 months from the date of issue.

162,500 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 30 November 2023, being 12 months from the date of issue.

50,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 1 December 2023, being 12 months from the date of issue.

7,500,000 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 23 June 2024, being 12 months from the date of issue.

13,500,000 options exercisable at \$0.30 on or before 22 August 2026, classified by ASX as restricted securities and to be held in escrow until 22 August 2025, being 24 months from the date of Quotation.

Other securities not quoted

500,000 options exercisable at \$0.30 on or before 22 August 2026

What do I need to do and by when?

For further information, please refer to COV's Replacement Prospectus.

Need more information?

For further information, please call the Share Registry, XCEND Pty Ltd on (02) 7208 8033 (within Australia) or +61 (2) 72008 8033 (Outside Australia) 8:30am to 5:00pm (AEDT) Monday to Friday during the offer period.



Disclaimer

Please refer to the following [disclaimer](#).

Issued by

Belinda Chiu

Senior Adviser, Listings Compliance